Press Release Details
Twist Bioscience Highlights Synthetic Libraries and High Throughput Antibody Discovery Platform at PEGS Boston 2022
-- Writing the Future of Biologics Presentation on
-- Rapid, Function-Forward mAb Discovery against a Cell Surface Target via Concurrent Use of Humanized and Hyperimmune Mice Presentation on
“These posters show the depth and breadth of the antibody discovery and library construction capabilities of Twist Biopharma against high-impact targets,” said Emily M. Leproust, Ph.D., CEO and co-founder of
Poster Number: P003
Advanced Antibody Discovery Workflow to Capture Maximum Repertoire Diversity
The complexity of antibody therapeutic targets continues to evolve, which in turn necessitates the evolution of integrated discovery methodologies. Incorporating state-of-the-art, high-resolution techniques enables reliable candidate triage more efficiently than traditional techniques. Major advancements in critical tools have improved antibody discovery by providing robust and thorough analysis of target specificity, function, and developability earlier in the drug development process. Effective integration of these technologies bolsters the antibody discovery process and facilitates lead candidate selection within as few as two months.
Poster Number: P004
In Vivo VHH Discovery Workflow Based on Immunized Alpaca and Rapid Beacon-Based Single B Cell Screening
VHH antibodies have demonstrated tremendous promise as versatile building blocks for antibody-based therapeutics, multispecifics and cell-based biologics due to higher affinity and better access to hidden epitopes on cell surface targets as compared to conventional IgG antibodies. Effective integration of advanced tools for analysis of target specificity, function and developability can bolster the VHH discovery process and facilitate lead candidate selection for novel therapeutic modalities against traditionally challenging targets.
Poster Number: P143
This poster details Twist’s next generation libraries including CRISPR gRNA libraries, which are an efficient tool for high throughput gene editing and knockout of molecular targets; synonymous codon (SynCodon) libraries, which are optimized to improve protein yields, binding affinity, stability, and expression of proteins; and T cell receptor (TCR) and chimeric antigen receptor (CAR) T cell libraries, which can be used in combination to screen a large scale of module sets.
Poster Number: P144
Discovery of Pre-clinical ADORA2A Antibody with Twist High Throughput Antibody Discovery Platform
These data detail how Twist used its high-throughput DNA synthesis platform and a large-scale phage library built based on a mouse immunization platform from Abveris, a division of
Poster Number: P145
Engineering Synthetic Multivalent VHH Antibodies at Scale
These data describe Twist’s scalable process for engineering high affinity mono and bispecific multivalent VHH-Fc antibodies against the SARS-CoV-2 spike protein.
Poster Number: P146
This poster demonstrates how Twist discovered high-affinity antibodies for six cytokine or immunomodulatory targets by constructing synthetic antibody libraries, using phage display to pan libraries against biotinylated protein targets, and screening for lead candidates through ELISA binding assays and NGS enrichment tracking.
About Twist Biopharma
By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005355/en/
SVP, Corporate Affairs